Advocacy intelligence hub — real-time data for patient organizations
City of Hope Medical Center — PHASE1
University of Washington — PHASE2
National Cancer Institute (NCI) — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs3
Phyrago
Handa Therapeutics, LLC
Scemblix
Novartis Pharmaceuticals Corporation
Imatinib Mesylate
Mylan Institutional Inc
Imatinib Mesylate
(IMATINIB MESYLATE)Orphan drugstandardApotex Corp
12.1 Mechanism of Action Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal...
Scemblix
(asciminib)Orphan drugacceleratedNovartis Pharmaceuticals Corporation
12.1 Mechanism of Action Asciminib is an ABL/BCR-ABL1 tyrosine kinase inhibitor. Asciminib inhibits the ABL1 kinase activity of the BCR::ABL1 fusion p...
Phyrago
(dasatinib)Orphan drugstandardHanda Therapeutics, LLC
12.1 Mechanism of Action Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA...
Imatinib Mesylate
(IMATINIB)Orphan drugstandardMylan Institutional Inc
12.1 Mechanism of Action Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal...
Imkeldi
(IMATINIB ORAL)Orphan drugstandardShorla Oncology Inc.,
12.1 Mechanism of Action Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal...
Browse all B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) news →
Farhad Ravandi-Kashani, M.D
SWOG Cancer Research Network
📍 HOUSTON, TX
Elias Jabbour, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Elias Jabbour, MD, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Anne L Angiolillo, MD
Children's Oncology Group
📍 WASHINGTON, DC
Etan Orgel, MD, MS
Children's Oncology Group
📍 LOS ANGELES, CA
Nitin Jain
M.D. Anderson Cancer Center
View all B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) specialists →